Access Bio

Access Bio was founded in 2002 in New Jersey, USA and listed on KOSDAQ in May 2013 as an in-vitro diagnostics company, with its core business centered on developing, manufacturing and selling rapid diagnostic tests (RDTs) for infectious diseases including malaria, HIV, influenza, dengue and COVID-19.

Before the pandemic, malaria rapid test kits accounted for more than 80% of revenue, and these products are sold almost entirely for export to lower-income regions in Africa and Southeast Asia through tenders run by organizations such as the WHO and UNICEF, which limits profitability.

In 2019 Woorideul Pharm (now Pharmgen Science) acquired management control and became the largest shareholder, a position it still holds with roughly a 24% stake.

During the COVID-19 pandemic the company obtained five separate US FDA Emergency Use Authorizations covering antigen, self-test, molecular (RT-PCR) and antibody diagnostics, which rapidly shifted its revenue mix toward COVID-19 test kits.

More recently the company has pursued product diversification built on its high-sensitivity CareSuperb diagnostic platform, following its standalone COVID-19 test with a combined COVID-19/flu antigen home test.

In January 2026 the board approved a KRW 57 billion investment to acquire an 80.2% stake in aesthetic company RF Bio, expanding into polynucleotide (PN)/PDRN-based skin boosters and hyaluronic acid (HA) fillers.

Alongside this, the company invested KRW 15 billion in medical aesthetics operator AAC Holdings and KRW 5 billion in joint venture AACG, aiming to build a wellness platform spanning diagnosis, procedures/care, monitoring and data.

On the competitive front, domestic diagnostics peers such as Humasis, SD Biosensor, Sugentech and Labgenomics face similar post-pandemic revenue restructuring pressures.

Its domestic manufacturing subsidiary Access Bio Korea, based in Goryeong-gun, North Gyeongsang Province, was dissolved in April 2026, reflecting a shrinking domestic production footprint.

Earnings have moved through a sharp contraction phase as the pandemic-driven boom faded.

Consolidated revenue fell from KRW 1.108 trillion in 2022 (operating margin 45.4%) to KRW 369.8 billion in 2023 (margin 6.2%), then to KRW 114.2 billion in 2024, where the company swung to an operating loss of KRW 4.3 billion (margin -3.8%).

In 2025, revenue shrank further to KRW 30.4 billion while the operating loss widened sharply to KRW 61.7 billion (margin -202.7%), meaning the loss was more than double the size of revenue itself.

On an owners' net income basis, losses that were KRW -3.4 billion in 2023 and roughly KRW -0.4 billion in 2024 ballooned to KRW -79.9 billion in 2025.

Quarterly, losses persisted from Q2 2025 (revenue KRW 1.3 billion, operating loss KRW 18.8 billion) through Q3 (revenue KRW 3.5 billion, operating loss KRW 13.6 billion) to Q4 (revenue KRW 4.9 billion, operating loss KRW 21.4 billion), with Q4's owners' net loss of KRW 52.4 billion notably larger than other quarters.

In 2026, revenue recovered modestly to KRW 5.1 billion in Q1 and KRW 8.9 billion in Q2, but operating losses of KRW 10.7 billion and KRW 22.1 billion respectively remained far larger than revenue. Over the most recent four quarters (Q3 2025 through Q2 2026), the cumulative owners' net loss reached KRW 106.2 billion.

Cash flow also turned negative, with 2025 operating cash flow at KRW -28.2 billion, signaling that the cash reserves accumulated during the pandemic era are being drawn down.

On the other hand, total equity declined from KRW 684.0 billion in 2022 to KRW 538.9 billion in 2025, but the debt ratio of 8.9% indicates the balance sheet itself carries relatively limited structural risk.

The in-vitro diagnostics industry is in a downcycle as COVID-19 test demand normalizes, lowering the overall revenue base across the sector. Access Bio's share of revenue from COVID-19 rapid tests fell from 92.9% in Q1 2022 to just 8% in Q1 2026, alongside a sharp drop in related production utilization.

Over the same period, Q1 COVID-19 RDT production volume collapsed from 117.9 million tests in 2022 to 130,000 tests in 2026, underscoring the business's increasingly standby-like character.

Still, recent confirmation that the company's existing test kit remains effective against the Omicron subvariant known as 'Cicada' (BA.3.2) has prompted a re-examination of the residual technical viability of its COVID-19 diagnostic platform amid renewed variant activity.

Domestic diagnostics-related stocks continue to move together whenever infectious-disease news such as hantavirus concerns surfaces, showing the sector still carries a thematic, headline-sensitive character.

The malaria diagnostics segment is driven mainly by public procurement through organizations such as the WHO and UNICEF, making it more a stability-oriented than a growth market.

In contrast, the domestic medical aesthetics market that Access Bio has newly entered is forecast by market researcher H&I Global Research to exceed KRW 1 trillion by 2033, representing a distinct supply-demand structure from its legacy diagnostics business.

Within this new segment, HA fillers and PDRN skin boosters via RF Bio are being marketed mainly for export to emerging markets in China, Southeast Asia and Latin America, making the pace of domestic and overseas regulatory approvals a key point to watch.

The company's strategic focus is on diversifying beyond a single diagnostics business.

Its combined COVID-19/flu antigen self-test, which received FDA 510(k) clearance in August 2025, is planned for expanded distribution through major North American retail networks such as CVS, Walgreens and Target ahead of the 2025-2026 winter respiratory season, with public procurement channels also being pursued; the company has stated it expects a competitive edge from conducting the entire development-to-delivery process within the United States amid a tightening Buy American Act policy stance.

The RF Bio acquisition requires a determination from the Ministry of Trade, Industry and Energy on whether RF Bio's core technology qualifies as a national core technology, plus prior approval for the cross-border M&A, with the approval process expected to take roughly 45 to 90 days.

In parallel, the company is pursuing investments in medical aesthetics operator AAC Holdings and joint venture AACG to build a personalized wellness platform spanning diagnosis, procedures/care, monitoring and data, while also taking an equity stake in beauty brand AJ Look to broaden its portfolio.

On shareholder returns, the board resolved in September 2025 to cancel all treasury shares, which was approved at the March 2026 shareholder meeting and completed in May 2026, reducing shares outstanding by 6.8%.

Regarding COVID-19, following confirmation of continued effectiveness against an Omicron subvariant, the company says it will keep evaluating potential uses for its CareSuperb platform.

Still, as the company itself has noted, maintaining production and distribution capacity that can respond quickly to market needs is the key challenge, and the actual timing and scale of any demand recovery remain unconfirmed.